Key result
Clinicians managing antithrombotics in advanced cancer report role ambiguity and a passive culture of continuation.
Why the study?
Antithrombotic therapy decision-making near the end of life in advanced cancer involves clinical uncertainty and blurred specialty roles, but clinicians' perspectives remain largely underexplored.
Design
Multinational qualitative semistructured interview study
Authors
Loading...
Supports caution against passive antithrombotic continuation in advanced cancer; leaves open optimal deprescribing strategies for prospective study.
Clinicians face significant complexities and ambiguity in managing antithrombotic therapy for advanced cancer patients at the end of life, often defaulting to a culture of continuation.
Baddeley et al. (2026) studied Advanced cancer at the end of life (n=80). Antithrombotic therapy management was evaluated on Clinicians' experiences of current practice of continuing and deprescribing ATT. Clinicians managing antithrombotic therapy in advanced cancer reported challenges including role ambiguity, timing delicacy, and a culture of continuation leading to passivity in therapy review.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: